| Caveolin-1 Protein | |
|---|---|
| Protein Name | Caveolin-1 |
| Gene Symbol | [CAV1](/genes/cav1) |
| UniProt ID | [Q03135](https://www.uniprot.org/uniprot/Q03135) |
| PDB Structure | 1DG6, 4HID |
| Molecular Weight | 22 kDa (178 aa) |
| Subcellular Location | Plasma membrane, caveolae, endosomes, Golgi |
| Protein Family | Caveolin family |
| Expression | Neurons, astrocytes, endothelial cells |
Caveolin-1 (CAV1) is a 22 kDa scaffolding protein that serves as the primary structural component of caveolae— flask-shaped invaginations of the plasma membrane. Beyond its well-characterized role in membrane organization, CAV1 plays critical roles in neuronal function, synaptic plasticity, and has emerged as a significant player in neurodegenerative disease pathogenesis [1].
Caveolae constitute approximately 15-20% of the neuronal plasma membrane surface and serve as critical signaling platforms that concentrate receptors, second messengers, and downstream effectors [6]. The caveolin protein family includes CAV1, CAV2, and CAV3, with CAV1 being the most widely expressed in the central nervous system.
Caveolin-1 contains several distinct structural domains:
The protein forms homooligomers of approximately 16-24 monomers that assemble into the characteristic caveolae structure [6]. Each CAV1 monomer has a hydrophobic hairpin that inserts into the inner leaflet of the plasma membrane, creating the characteristic flask-shaped invagination.
CAV1 undergoes several important post-translational modifications:
In neurons, CAV1 is enriched at synaptic membranes where it serves several essential functions:
CAV1 regulates endocytic and exocytic trafficking pathways critical for synaptic vesicle recycling and neurotransmitter release. The protein interacts with components of the endocytic machinery including dynamin and clathrin adaptor proteins.
CAV1 provides neuroprotective effects through multiple mechanisms [4]:
Recent research has revealed a critical role for CAV1 in amyloid-β (Aβ) uptake and toxicity [2]. The cellular prion protein (PrP^C) acts as a mediator of Aβ uptake by CAV1, leading to:
CAV1 expression is altered in Alzheimer's disease brains, contributing to synaptic loss:
Gene therapy approaches using neuron-targeted CAV1 overexpression have shown promise [5]:
The Synapsin-CAV1 fusion construct enables neuron-specific expression and represents a promising therapeutic strategy for AD.
In Parkinson's disease, CAV1 is implicated in:
Several strategies are being explored to target CAV1 in neurodegeneration:
Caveolin-1 is a multifunctional scaffolding protein essential for neuronal health. Through its role in organizing caveolae, regulating synaptic signaling, and maintaining cellular homeostasis, CAV1 provides critical neuroprotective functions. In Alzheimer's disease, loss of CAV1 function contributes to synaptic dysfunction and cognitive decline, while its interaction with amyloid-β and the cellular prion protein reveals new pathological mechanisms. Therapeutic approaches targeting CAV1, particularly through gene therapy, represent a promising avenue for disease-modifying treatment in neurodegeneration.